Calcitonin gene-related peptide, adrenomedullin and flushing

Debbie L. Hay, David R. Poyner

Research output: Contribution to journalArticle

Abstract

Administration of calcitonin gene-related peptide (CGRP) or adrenomedullin (AM) can cause facial flushing, suggesting that the peptides may be important in hot flushes experienced particularly by post-menopausal women. Five studies have measured plasma CGRP concentrations in post-menopausal women who suffer from flushes; all demonstrated elevations of between 170% and 320% over control. Three of the studies showed a temporal relationship between flushes and CGRP elevation. A further study has shown that CGRP is elevated in the urine of women who suffer from flushes. Only a single study has investigated flushes in pre-menopausal women; no elevation of CGRP was observed. Flushes are also experienced by men undergoing androgen deprivation therapy. Whilst one study failed to find any increase in CGRP in the urine of these individuals, a small study has identified an increase in plasma CGRP. No studies have investigated plasma AM or the related peptide, intermedin/AM2. Overall, there is good evidence to show that flushes in post-menopausal women are accompanied by an increase in CGRP. CGRP could act centrally on the thermoregulatory centre of the hypothalamus as well as peripherally to cause vasodilation and sweating. However, it remains to be demonstrated that the elevated CGRP causes flushes. Recently developed CGRP antagonists provide an opportunity to test this hypothesis. If they are successful, they may represent a useful alternative to oestrogen replacement therapy.
Original languageEnglish
Pages (from-to)104-108
Number of pages5
JournalMaturitas
Volume64
Issue number2
Early online date16 Sep 2009
DOIs
Publication statusPublished - 20 Oct 2009

Fingerprint

Adrenomedullin
Calcitonin Gene-Related Peptide
Plasmas
Urine
Peptides
Estrogen Replacement Therapy
Sweating
Vasodilation
Androgens
Hypothalamus
Estrogens

Keywords

  • adrenomedullin
  • calcitonin gene-related peptide
  • female
  • hot flashes
  • humans
  • male
  • postmenopause
  • peripheral vasodilation

Cite this

Hay, Debbie L. ; Poyner, David R. / Calcitonin gene-related peptide, adrenomedullin and flushing. In: Maturitas. 2009 ; Vol. 64, No. 2. pp. 104-108.
@article{f9b0d2b734b045269db650af38b02df8,
title = "Calcitonin gene-related peptide, adrenomedullin and flushing",
abstract = "Administration of calcitonin gene-related peptide (CGRP) or adrenomedullin (AM) can cause facial flushing, suggesting that the peptides may be important in hot flushes experienced particularly by post-menopausal women. Five studies have measured plasma CGRP concentrations in post-menopausal women who suffer from flushes; all demonstrated elevations of between 170{\%} and 320{\%} over control. Three of the studies showed a temporal relationship between flushes and CGRP elevation. A further study has shown that CGRP is elevated in the urine of women who suffer from flushes. Only a single study has investigated flushes in pre-menopausal women; no elevation of CGRP was observed. Flushes are also experienced by men undergoing androgen deprivation therapy. Whilst one study failed to find any increase in CGRP in the urine of these individuals, a small study has identified an increase in plasma CGRP. No studies have investigated plasma AM or the related peptide, intermedin/AM2. Overall, there is good evidence to show that flushes in post-menopausal women are accompanied by an increase in CGRP. CGRP could act centrally on the thermoregulatory centre of the hypothalamus as well as peripherally to cause vasodilation and sweating. However, it remains to be demonstrated that the elevated CGRP causes flushes. Recently developed CGRP antagonists provide an opportunity to test this hypothesis. If they are successful, they may represent a useful alternative to oestrogen replacement therapy.",
keywords = "adrenomedullin, calcitonin gene-related peptide, female, hot flashes, humans, male, postmenopause, peripheral vasodilation",
author = "Hay, {Debbie L.} and Poyner, {David R.}",
year = "2009",
month = "10",
day = "20",
doi = "10.1016/j.maturitas.2009.08.011",
language = "English",
volume = "64",
pages = "104--108",
journal = "Maturitas",
issn = "0378-5122",
publisher = "Elsevier",
number = "2",

}

Calcitonin gene-related peptide, adrenomedullin and flushing. / Hay, Debbie L.; Poyner, David R.

In: Maturitas, Vol. 64, No. 2, 20.10.2009, p. 104-108.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Calcitonin gene-related peptide, adrenomedullin and flushing

AU - Hay, Debbie L.

AU - Poyner, David R.

PY - 2009/10/20

Y1 - 2009/10/20

N2 - Administration of calcitonin gene-related peptide (CGRP) or adrenomedullin (AM) can cause facial flushing, suggesting that the peptides may be important in hot flushes experienced particularly by post-menopausal women. Five studies have measured plasma CGRP concentrations in post-menopausal women who suffer from flushes; all demonstrated elevations of between 170% and 320% over control. Three of the studies showed a temporal relationship between flushes and CGRP elevation. A further study has shown that CGRP is elevated in the urine of women who suffer from flushes. Only a single study has investigated flushes in pre-menopausal women; no elevation of CGRP was observed. Flushes are also experienced by men undergoing androgen deprivation therapy. Whilst one study failed to find any increase in CGRP in the urine of these individuals, a small study has identified an increase in plasma CGRP. No studies have investigated plasma AM or the related peptide, intermedin/AM2. Overall, there is good evidence to show that flushes in post-menopausal women are accompanied by an increase in CGRP. CGRP could act centrally on the thermoregulatory centre of the hypothalamus as well as peripherally to cause vasodilation and sweating. However, it remains to be demonstrated that the elevated CGRP causes flushes. Recently developed CGRP antagonists provide an opportunity to test this hypothesis. If they are successful, they may represent a useful alternative to oestrogen replacement therapy.

AB - Administration of calcitonin gene-related peptide (CGRP) or adrenomedullin (AM) can cause facial flushing, suggesting that the peptides may be important in hot flushes experienced particularly by post-menopausal women. Five studies have measured plasma CGRP concentrations in post-menopausal women who suffer from flushes; all demonstrated elevations of between 170% and 320% over control. Three of the studies showed a temporal relationship between flushes and CGRP elevation. A further study has shown that CGRP is elevated in the urine of women who suffer from flushes. Only a single study has investigated flushes in pre-menopausal women; no elevation of CGRP was observed. Flushes are also experienced by men undergoing androgen deprivation therapy. Whilst one study failed to find any increase in CGRP in the urine of these individuals, a small study has identified an increase in plasma CGRP. No studies have investigated plasma AM or the related peptide, intermedin/AM2. Overall, there is good evidence to show that flushes in post-menopausal women are accompanied by an increase in CGRP. CGRP could act centrally on the thermoregulatory centre of the hypothalamus as well as peripherally to cause vasodilation and sweating. However, it remains to be demonstrated that the elevated CGRP causes flushes. Recently developed CGRP antagonists provide an opportunity to test this hypothesis. If they are successful, they may represent a useful alternative to oestrogen replacement therapy.

KW - adrenomedullin

KW - calcitonin gene-related peptide

KW - female

KW - hot flashes

KW - humans

KW - male

KW - postmenopause

KW - peripheral vasodilation

UR - http://www.scopus.com/inward/record.url?scp=70349738088&partnerID=8YFLogxK

U2 - 10.1016/j.maturitas.2009.08.011

DO - 10.1016/j.maturitas.2009.08.011

M3 - Article

VL - 64

SP - 104

EP - 108

JO - Maturitas

JF - Maturitas

SN - 0378-5122

IS - 2

ER -